Ivermectin in Treatment of COVID-19

Phase 2

• Conditions: COVID
• Interventions: Drug: Ivermectin

• Registration Number: NCT04445311
• Lead Sponsor: Zagazig University

Brief Summary

confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-31
• Status Verified: 2020-06
• Study First Submitted: 2020-06-19
• Study First Submitted QC: 2020-06-19
• Last Update Submitted: 2020-06-19
• Study First Posted: 2020-06-24
• Last Update Posted: 2020-06-24
• Primary Completion: 2020-07-30
• Study Completion: 2020-08-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

COVID-19 patients during period of the study more than 18 years old

Exclusion Criteria

refuse to participate pregnancy or lactation hypersensitivity to ivermectin receive any drug with interaction with ivermectin

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ivermectin group	Ivermectin	group that will receive ivermectin plus standard of care ttt

Primary Outcome Measures

Name	Time	Method
time to be symptoms free	within 21 days after enrollment	duration from day 1 symptoms till 3 days without symptoms

Secondary Outcome Measures

Name	Time	Method
Mechanical ventilation	within 21 days after enrollement	need mechanical ventilation
hospitalization	within 21 days after enrollement	need hospital admission
length of stay	within one month days after enrollement	days spent in hospital
mortality	within one month days after enrollement	survived or died

Trial Locations

Locations (1)

Waheed Shouman; 🇪🇬 Zagazig, Sharkia, Egypt